Literature DB >> 8485649

Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines.

H N Nguyen1, B U Sevin, H E Averette, J Perras, R Ramos, D Donato, K Ochiai, M Penalver.   

Abstract

Cisplatin continues to be one of the most commonly used cytotoxic agent. Problems of drug resistance and nephrotoxicity have generated interest in new platinum derivatives. In this study, we used flow cytometry to study their effects on cell kinetics and to see if the extent of cell cycle perturbations can be used to determine relative potency. The following four platinum derivatives were tested: cisplatin, carboplatin, 254S, and NK121 on two human ovarian cancer cell lines: BG1 and CAOV3. Flow cytometric analysis revealed a dynamic spectrum of cell kinetic perturbations, which included sequential S-G2 block, concomitant S-G2 block, and a dominant S block with abolition of G2 block. Platinum derivatives NK121, 254S, and CARBO induced an average of 54.5 +/- 5.6, 21.2 +/- 5.5, and 2.5 +/- 2.8% more S-G2 blocks than cisplatin, respectively. When comparing the severity of S-G2 blocks and requiring a p-value of 0.05, the order of increasing potency was: cisplatin, carboplatin, 254S, and NK121.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485649     DOI: 10.3109/07357909309024851

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  9 in total

1.  Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: dependence on the tumor sensitivity to cisplatin.

Authors:  M C Jäckel; R Tausch-Treml; P Köpf-Maier
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin.

Authors:  Tracy M Neher; Diane Bodenmiller; Richard W Fitch; Shadia I Jalal; John J Turchi
Journal:  Mol Cancer Ther       Date:  2011-08-16       Impact factor: 6.261

3.  Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.

Authors:  Viktor Horváth; Karel Soucek; Lenka Svihálková-Sindlerová; Jan Vondrácek; Olga Blanárová; Jirina Hofmanová; Petr Sova; Alois Kozubík
Journal:  Invest New Drugs       Date:  2007-05-23       Impact factor: 3.850

4.  Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.

Authors:  Preetinder P Singh; Swapna Joshi; Pamela J Russell; Sham Nair; Aparajita Khatri
Journal:  BMC Cancer       Date:  2011-08-24       Impact factor: 4.430

5.  The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.

Authors:  N Iizuka; K Hirose; T Noma; S Hazama; A Tangoku; H Hayashi; T Abe; K Yamamoto; M Oka
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

6.  Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.

Authors:  Jose F Ponte; Olga Ab; Leanne Lanieri; Jenny Lee; Jennifer Coccia; Laura M Bartle; Marian Themeles; Yinghui Zhou; Jan Pinkas; Rodrigo Ruiz-Soto
Journal:  Neoplasia       Date:  2016-11-25       Impact factor: 5.715

7.  Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.

Authors:  Rosaria Chilà; Terence Hall G; Giovanni Abbadessa; Massimo Broggini; Giovanna Damia
Journal:  Transl Oncol       Date:  2017-02-03       Impact factor: 4.243

8.  Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.

Authors:  V Cepero; B García-Serrelde; V Moneo; F Blanco; A M González-Vadillo; A Alvarez-Valdés; C Navarro-Ranninger; A Carnero
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.340

9.  The role of AtMUS81 in interference-insensitive crossovers in A. thaliana.

Authors:  Luke E Berchowitz; Kirk E Francis; Alexandra L Bey; Gregory P Copenhaver
Journal:  PLoS Genet       Date:  2007-06-26       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.